Jeff Giullian, chief medical officer for DaVita, said at the time, adding, Based on the inclusion criteria for study participants, we believe there may be limited application of the FLOW study findings to the overall CKD patient population. He argued that the inclusion requirements necessary to partake in the FLOW trial, such as needing to be on a standard kidney disease treatment and have a certain amount of protein in the urine, were attributable to a narrow subset less than 10% of all current CKD patients
These results were more profound in women and older adults
PlexusDx provides hydration and electrolyte guidance as part of your monthly monitoring, adjusting recommendations based on your individual response patterns and genetic insights from the Precision Peptide Test
[26] History [edit] During the early 1980s, Jean-Pierre Raufman worked as a postdoctoral researcher at the National Institutes of Health for John Pisano, an "eccentric biochemist" who specialized in collecting venoms from various animals and looking for novel substances that could affect human physiology